SCHEMBL109355

SCHEMBL109355

CCCCOC(=O)C(O)SC(O)C(=O)OCCCC

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
ATM Q13315 1/20 0.48
TSHR P16473 5/20 0.45
HPGD P15428 1/20 0.45
HCAR2 Q8TDS4 1/20 0.42
NAAA Q02083 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX1 P07099 1/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
NR1H2 P55055 1/20 0.39
RNASEL Q05823 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACHE P22303 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111427 0.92 NAAA (0.53) ALDH1A1TSHRHCAR2NAAAEPHX1
SCHEMBL110462 0.92 NAAA (0.53) ALDH1A1TSHRHCAR2NAAAEPHX1
SCHEMBL112352 0.92 NAAA (0.53) ALDH1A1TSHRHCAR2NAAAEPHX1
SCHEMBL111061 0.92 NAAA (0.53) ALDH1A1TSHRHCAR2NAAAEPHX1
SCHEMBL111432 0.86 HCAR2 (0.39) ALDH1A1ATMTSHRHCAR2TDP1
SCHEMBL11442079 0.85 NAAA (0.47) TSHRHCAR2NAAAEPHX1SMN1; SMN2
SCHEMBL74371 0.79 ALDH1A1 (0.58) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL8637991 0.79 ALDH1A1 (0.58) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL10731279 0.79 ALDH1A1 (0.58) ALDH1A1ATMTSHRHPGDHCAR2
SCHEMBL9504230 0.79 ALDH1A1 (0.58) ALDH1A1ATMTSHRHPGDHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000659-B2 Insulating layer-forming composition and use thereof HILTI AKTIENGESELLSCHAFT (LI) 2018-06-19 US claimed
US-20150275031-A1 INSULATING LAYER-FORMING COMPOSITION AND USE THEREOF HILTI AKTIENGESELLSCHAFT (LI) 2015-10-01 US claimed
CN-102802605-A Stable lipid formulations of apoptosis promoters ABBOTT LAB 2012-11-28 CN claimed
EP-2424499-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER Abbott Laboratories (US) 2012-03-07 EP claimed
WO-2010127193-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO claimed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 US claimed
US-12351659-B2 Curable composition comprising a photoinitiator ARKEMA FRANCE (FR) 2025-07-08 US disclosed
US-20240199770-A1 CURABLE COMPOSITION COMPRISING A PHOTOINITIATOR ARKEMA FRANCE (FR) 2024-06-20 US disclosed
US-10000659-B2 Insulating layer-forming composition and use thereof HILTI AKTIENGESELLSCHAFT (LI) 2018-06-19 US disclosed
US-20150275031-A1 INSULATING LAYER-FORMING COMPOSITION AND USE THEREOF HILTI AKTIENGESELLSCHAFT (LI) 2015-10-01 US disclosed
CN-102802605-B Stable lipid formulations of apoptosis promoters ABBVIE (US) 2015-08-12 CN disclosed
US-8927009-B2 ABT-263 capsule ABBVIE INC. (US) 2015-01-06 US disclosed
US-8728516-B2 Stabilized lipid formulation of apoptosis promoter ABBVIE INC. (US) 2014-05-20 US disclosed
WO-2010127198-A1 FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
WO-2010127193-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER ABBVIE INC. 2010-11-04 US disclosed
WO-2010127190-A1 SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF ABBOTT LABORATORIES (US) 2010-11-04 WO disclosed
US-7642371-B2 Process for preparing dialkyl thiodiglycolates SALTIGO GMBH (DE) 2010-01-05 US disclosed
US-20090163736-A1 PROCESS FOR PREPARING DIALKYL THIODIGLYCOLATES SALTIGO GMBH (DE) 2009-06-25 US disclosed
EP-2072499-A1 Method for manufacturing thiodiglycolic dialkyl esters Saltigo GmbH (DE) 2009-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351659-B2 Curable composition comprising a photoinitiator EED, CDH1, EPB41 ALDH1A1 1379/4885ATM 1324/4885TSHR 4782/4885
US-20100278905-A1 STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER BCL2, BAX, BCOR ALDH1A1 3985/4885ATM 2737/4885TSHR 4319/4885
US-20240199770-A1 CURABLE COMPOSITION COMPRISING A PHOTOINITIATOR EED, CDH1, EPB41 ALDH1A1 1379/4885ATM 1324/4885TSHR 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.